Status:
COMPLETED
Immuno-molecular Approaches for Non-invasive Diagnosis of Prostate Cancer
Lead Sponsor:
Assistance Publique - Hôpitaux de Paris
Collaborating Sponsors:
Rarecells Diagnostics SAS
Institut National de la Santé Et de la Recherche Médicale, France
Conditions:
Prostate Cancer
Eligibility:
MALE
Brief Summary
The purpose of this study is to isolate and characterize tumor cells non-invasively from biological samples in patients with prostate cancer and demonstrate the ability to identify the presence and nu...
Detailed Description
Prostate cancer is one of the most frequently diagnosed cancers and a leading cause of cancer death in men worldwide. Existing methods of diagnosis and monitoring of prostate cancer are inadequate due...
Eligibility Criteria
Inclusion
- Patients with a diagnosis of localized or metastatic prostate cancer.
- No prior or other oncological treatment.
- Patients undergoing prostate biopsy in the context of prostate cancer diagnosis.
- Patients with an elevation of PSA (Prostate Specific Antigen), an abnormality on the rectal examination and / or an MRI signal motivating a prostate biopsy,
- Patients informed and not opposed to participating in the research
Exclusion
- Patients not affiliated with French social security.
- Patients unable to understand the protocol.
- Patients diagnosed with another type of cancer within the past 5 years.
- Patients prostatectomized and/or treated for prostate cancer.
- Patients who wear a bladder catheter
- Patients under guardianship or curatorship
- Patients under AME
Key Trial Info
Start Date :
March 19 2021
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
May 30 2022
Estimated Enrollment :
127 Patients enrolled
Trial Details
Trial ID
NCT04702633
Start Date
March 19 2021
End Date
May 30 2022
Last Update
November 20 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Cochin Hospital
Paris, France, 75014